OC
IDNA icon

Opal Capital’s iShares Genomics Immunology and Healthcare ETF IDNA Stock Holding History

Opal Capital’s Portfolio IDNA Stock Details IDNA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-6,550
Closed -$604K – 167
2025
Q4 		$604K Buy
+6,550
New +$168K 0.15% 95

Other funds holding IDNA

UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return
WBG
Wharton Business Group Malvern, Pennsylvania $2.99B AUM 30.41% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $495B AUM 43.24% 1-Year Est. Return
PGA
Portland Global Advisors Portland, Maine $1.05B AUM 18.22% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Raymond James Financial
Raymond James Financial St Petersburg, Florida $369B AUM 28.27% 1-Year Est. Return
LPL Financial
LPL Financial San Diego, California $445B AUM 25.58% 1-Year Est. Return
Royal Bank of Canada
Royal Bank of Canada Toronto, Ontario, Canada $672B AUM 33.48% 1-Year Est. Return
CCA
Clearwater Capital Advisors Hoffman Estates, Illinois $1.36B AUM 18.79% 1-Year Est. Return

Opal Capital's IDNA Position: Q1 2026 in Review

Opal Capital sold out of iShares Genomics Immunology and Healthcare ETF (IDNA) in Q1 2026, closing a stake of 6,550 shares — an estimated $604K sold.

Opal Capital first reported a position in IDNA in Q4 2025 and held it in 1 quarter. The position peaked at $604K in Q4 2025. 60 funds tracked by Wall St. Rank hold IDNA as of Q1 2026.

  • Opal Capital reported no remaining iShares Genomics Immunology and Healthcare ETF position as of Q1 2026 after selling out during the quarter.
  • Opal Capital sold 6,550 iShares Genomics Immunology and Healthcare ETF shares in Q1 2026, an estimated $604K.
  • Opal Capital first reported a position in iShares Genomics Immunology and Healthcare ETF in Q4 2025 and held it in 1 quarter.
  • Opal Capital's iShares Genomics Immunology and Healthcare ETF position peaked at $604K in Q4 2025.
  • 60 funds tracked by Wall St. Rank held iShares Genomics Immunology and Healthcare ETF as of Q1 2026.

Based on Opal Capital's 13F filing for Q1 2026, filed 18 May 2026.